Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL874036 | 0.87 | PPIB (0.35) | DUTCYP19A1MAPTHPGDMEN1 | |
| SCHEMBL873832 | 0.78 | AKT1 (0.49) | DUTPBRM1MAPTHPGDKMT2A | |
| SCHEMBL8511469 | 0.73 | AKT1 (0.46) | DUTPBRM1MAPTHPGDKMT2A | |
| SCHEMBL874944 | 0.72 | DUT (0.32) | DUT | |
| SCHEMBL1981849 | 0.68 | AKT1 (0.42) | PBRM1MAPTHPGDKMT2A | |
| SCHEMBL10237757 | 0.66 | AKT1 (0.47) | DUTMAPTHPGDKMT2A | |
| SCHEMBL875050 | 0.65 | AKT1 (0.46) | MAPTHPGDMEN1KMT2A | |
| SCHEMBL10237758 | 0.63 | KDM4E (0.33) | DUT | |
| SCHEMBL4056078 | 0.63 | PTGDR2 (0.40) | DUTHPGDMEN1KMT2A | |
| SCHEMBL8515929 | 0.62 | KDM4E (0.34) | DUTMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083501-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | BACE1, PSEN1, PSEN2 | DUT 3495/4885CYP19A1 2497/4885PBRM1 3853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.